Crossmark Global Holdings Inc. Sells 10,433 Shares of Jazz Pharmaceuticals PLC $JAZZ

Crossmark Global Holdings Inc. lessened its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 74.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,674 shares of the specialty pharmaceutical company’s stock after selling 10,433 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Jazz Pharmaceuticals were worth $484,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Vestal Point Capital LP bought a new stake in Jazz Pharmaceuticals during the second quarter worth $127,344,000. AQR Capital Management LLC grew its position in shares of Jazz Pharmaceuticals by 62.1% in the 2nd quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company’s stock valued at $84,341,000 after acquiring an additional 304,463 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Jazz Pharmaceuticals by 11.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock worth $373,855,000 after purchasing an additional 298,815 shares during the last quarter. Wedge Capital Management L L P NC acquired a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth about $27,834,000. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Jazz Pharmaceuticals by 147.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock valued at $43,652,000 after purchasing an additional 209,667 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Down 0.3%

Shares of JAZZ opened at $185.43 on Thursday. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $198.00. The firm has a market cap of $11.42 billion, a P/E ratio of -31.06, a price-to-earnings-growth ratio of 0.34 and a beta of 0.22. The firm’s 50-day simple moving average is $172.02 and its 200 day simple moving average is $155.43. The company has a debt-to-equity ratio of 1.00, a quick ratio of 1.67 and a current ratio of 1.86.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, beating the consensus estimate of $6.49 by $0.15. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The firm had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the prior year, the firm earned $6.51 EPS. The business’s revenue was up 8.1% on a year-over-year basis. On average, analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 55,600 shares of the company’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $191.56, for a total value of $10,650,736.00. Following the transaction, the executive vice president directly owned 56,862 shares of the company’s stock, valued at $10,892,484.72. This represents a 49.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 5,343 shares of the company’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $194.49, for a total value of $1,039,160.07. Following the completion of the transaction, the senior vice president directly owned 28,728 shares in the company, valued at approximately $5,587,308.72. This represents a 15.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 68,015 shares of company stock worth $13,037,486 in the last ninety days. 4.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Robert W. Baird raised their target price on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a research note on Tuesday, November 18th. Royal Bank Of Canada upped their price objective on Jazz Pharmaceuticals from $191.00 to $195.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Bank of America raised their price objective on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Morgan Stanley lifted their target price on Jazz Pharmaceuticals from $225.00 to $226.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Finally, UBS Group reissued a “neutral” rating and set a $188.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday, November 24th. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $214.38.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.